Hypoxia‐Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment‐Resistant Cancer Cells

• Published in: Advanced science Vol. 11; no. 34; pp. e2403831 - n/a
• Main Authors: Barnieh, Francis M., Morais, Goreti Ribeiro, Loadman, Paul M., Falconer, Robert A., El‐Khamisy, Sherif F.
• Format: Journal Article
• Language: English
• Published: Germany John Wiley & Sons, Inc 01.09.2024; John Wiley and Sons Inc; Wiley
• Subjects: Adaptation; Animals; Antineoplastic Agents - pharmacology; Ataxia Telangiectasia Mutated Proteins - antagonists & inhibitors; Ataxia Telangiectasia Mutated Proteins - metabolism; ATR; AZD6738; Breast cancer; Cancer therapies; Cell Line, Tumor; Clinical trials; Cytotoxicity; Disease Models, Animal; DNA damage; DNA repair; Drug Resistance, Neoplasm - drug effects; Genes; Humans; Hypoxia; Indoles; Kinases; Medical prognosis; Mice; Morpholines - pharmacology; Neoplasms - drug therapy; Neoplasms - metabolism; Phosphorylation; Prodrugs; Prodrugs - pharmacology; Proteins; Pyrimidines - pharmacology; Sulfonamides; Targeted Delivery; Toxicity; Tumors; AZD6738; Hypoxia; Prodrugs; DNA repair; ATR; Targeted Delivery

Targeted therapy remains the future of anti‐cancer drug development, owing to the lack of specificity of current treatments which lead to damage in healthy normal tissues. ATR inhibitors have in recent times demonstrated promising clinical potential, and are currently being evaluated in the clinic....